Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
9.38B | 9.21B | 10.58B | 10.48B | 8.47B | Gross Profit |
2.29B | 2.06B | 2.14B | 2.50B | 1.98B | EBIT |
1.30B | 1.09B | 1.25B | 1.88B | 968.00M | EBITDA |
1.80B | 1.81B | 1.73B | 2.42B | 1.54B | Net Income Common Stockholders |
905.00M | 894.00M | 793.00M | 857.00M | 478.00M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
837.00M | 548.00M | 493.00M | 459.00M | 564.00M | Total Assets |
15.21B | 14.63B | 14.67B | 15.52B | 16.08B | Total Debt |
5.02B | 4.97B | 5.15B | 5.16B | 5.62B | Net Debt |
4.18B | 4.42B | 4.66B | 4.70B | 5.05B | Total Liabilities |
9.36B | 9.10B | 9.43B | 9.73B | 9.97B | Stockholders Equity |
5.78B | 5.46B | 5.15B | 5.70B | 6.02B |
Cash Flow | Free Cash Flow | |||
688.00M | 541.00M | 351.00M | 1.04B | 1.07B | Operating Cash Flow |
1.29B | 1.37B | 975.00M | 1.62B | 1.46B | Investing Cash Flow |
-534.00M | -432.00M | 392.00M | -29.00M | -394.00M | Financing Cash Flow |
-454.00M | -888.00M | -1.32B | -1.69B | -704.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $10.72B | 12.13 | 16.11% | 3.50% | 1.91% | 2.94% | |
65 Neutral | $24.80B | 18.32 | 19.13% | 2.46% | -4.59% | 11.09% | |
59 Neutral | $23.76B | 17.69 | 10.69% | 7.17% | -1.46% | -36.00% | |
58 Neutral | $25.07B | 22.75 | 6.14% | 7.86% | -3.72% | 91.57% | |
57 Neutral | $2.67B | 21.03 | 0.18% | 2.86% | -4.35% | -115.63% | |
50 Neutral | $5.27B | 6.84 | -24.69% | 4.42% | -6.03% | -177.29% | |
47 Neutral | $2.64B | -4.00 | -31.55% | 3.33% | 2.93% | -29.90% |
Eastman Chemical Company, at its 2024 Circular Economy Deep Dive event, highlighted its strategy for significant EBITDA growth through circular economy initiatives, projecting over $2.1 billion in EBITDA in a normalized environment. With a commitment to innovation and sustainability, Eastman plans substantial investments in methanolysis projects and biopolymer platforms, aiming for $500 million additional EBITDA by 2029. This positions Eastman as a strong growth opportunity, leveraging economic recovery and strategic investments to secure future value.